UA72182C2 - Oral delayed immediate release formulation and method for its manufacture - Google Patents

Oral delayed immediate release formulation and method for its manufacture Download PDF

Info

Publication number: UA72182C2
Authority: UA; Ukraine
Prior art keywords: immediate; core; oral; coating; delayed
Prior art date: 1996-09-23

Application number

UA99042314A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Duphar Int Res

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-23

Filing date

1997-09-18

Publication date

2005-02-15

1997-09-18 Application filed by Duphar Int Res filed Critical Duphar Int Res

2005-02-15 Publication of UA72182C2 publication Critical patent/UA72182C2/uk

Links

239000012729 immediate-release (IR) formulation Substances 0.000 title claims abstract description 22
230000003111 delayed effect Effects 0.000 title claims abstract description 12
238000000034 method Methods 0.000 title claims abstract description 12
238000004519 manufacturing process Methods 0.000 title description 10
239000011248 coating agent Substances 0.000 claims abstract description 78
238000000576 coating method Methods 0.000 claims abstract description 78
150000001875 compounds Chemical class 0.000 claims abstract description 70
239000000203 mixture Substances 0.000 claims abstract description 46
239000013543 active substance Substances 0.000 claims abstract description 44
230000002496 gastric effect Effects 0.000 claims abstract description 15
239000012530 fluid Substances 0.000 claims abstract description 12
239000000969 carrier Substances 0.000 claims abstract description 9
108090000623 proteins and genes Proteins 0.000 claims abstract description 8
102000004169 proteins and genes Human genes 0.000 claims abstract description 8
230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 6
229960005486 vaccine Drugs 0.000 claims abstract description 6
230000001088 anti-asthma Effects 0.000 claims abstract description 4
239000000924 antiasthmatic agent Substances 0.000 claims abstract description 4
108090000790 Enzymes Proteins 0.000 claims abstract description 3
102000004190 Enzymes Human genes 0.000 claims abstract description 3
108091034117 Oligonucleotide Proteins 0.000 claims abstract description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims abstract description 3
230000002456 anti-arthritic effect Effects 0.000 claims abstract description 3
230000003474 anti-emetic effect Effects 0.000 claims abstract description 3
230000003356 anti-rheumatic effect Effects 0.000 claims abstract description 3
230000000767 anti-ulcer Effects 0.000 claims abstract description 3
239000000935 antidepressant agent Chemical class 0.000 claims abstract description 3
239000002111 antiemetic agent Substances 0.000 claims abstract description 3
239000003435 antirheumatic agent Substances 0.000 claims abstract description 3
239000002249 anxiolytic agent Chemical class 0.000 claims abstract description 3
230000003177 cardiotonic effect Effects 0.000 claims abstract description 3
239000003246 corticosteroid Substances 0.000 claims abstract description 3
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 3
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 3
239000000932 sedative agent Chemical class 0.000 claims abstract description 3
229940124549 vasodilator Drugs 0.000 claims abstract description 3
239000003071 vasodilator agent Substances 0.000 claims abstract description 3
238000009472 formulation Methods 0.000 claims abstract 3
230000002522 swelling effect Effects 0.000 claims abstract 3
230000000202 analgesic effect Effects 0.000 claims abstract 2
230000000049 anti-anxiety effect Effects 0.000 claims abstract 2
230000001430 anti-depressive effect Effects 0.000 claims abstract 2
230000003276 anti-hypertensive effect Effects 0.000 claims abstract 2
230000001362 anti-vertigo Effects 0.000 claims abstract 2
239000000463 material Substances 0.000 claims description 24
230000009471 action Effects 0.000 claims description 17
239000004014 plasticizer Substances 0.000 claims description 16
239000000454 talc Substances 0.000 claims description 12
229910052623 talc Inorganic materials 0.000 claims description 12
239000003795 chemical substances by application Substances 0.000 claims description 9
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 7
239000001856 Ethyl cellulose Substances 0.000 claims description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
239000002552 dosage form Substances 0.000 claims description 6
235000019325 ethyl cellulose Nutrition 0.000 claims description 6
229920001249 ethyl cellulose Polymers 0.000 claims description 6
230000009474 immediate action Effects 0.000 claims description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
239000002775 capsule Substances 0.000 claims description 5
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 5
ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 claims description 4
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical group CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 4
-1 cardiotonic Substances 0.000 claims description 4
239000001069 triethyl citrate Substances 0.000 claims description 4
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 4
235000013769 triethyl citrate Nutrition 0.000 claims description 4
235000019359 magnesium stearate Nutrition 0.000 claims description 3
229960002622 triacetin Drugs 0.000 claims description 3
229910002012 Aerosil® Inorganic materials 0.000 claims description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
230000003257 anti-anginal effect Effects 0.000 claims description 2
239000001087 glyceryl triacetate Substances 0.000 claims description 2
235000013773 glyceryl triacetate Nutrition 0.000 claims description 2
229960003971 influenza vaccine Drugs 0.000 claims description 2
235000013772 propylene glycol Nutrition 0.000 claims description 2
235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
239000006186 oral dosage form Substances 0.000 claims 7
239000002202 Polyethylene glycol Substances 0.000 claims 1
230000003288 anthiarrhythmic effect Effects 0.000 claims 1
239000003416 antiarrhythmic agent Substances 0.000 claims 1
230000000968 intestinal effect Effects 0.000 claims 1
239000008177 pharmaceutical agent Substances 0.000 claims 1
229920001223 polyethylene glycol Polymers 0.000 claims 1
230000001624 sedative effect Effects 0.000 claims 1
229940005513 antidepressants Drugs 0.000 abstract description 2
229940125683 antiemetic agent Drugs 0.000 abstract description 2
239000002220 antihypertensive agent Chemical class 0.000 abstract description 2
229940030600 antihypertensive agent Drugs 0.000 abstract description 2
239000000496 cardiotonic agent Substances 0.000 abstract description 2
229960001334 corticosteroids Drugs 0.000 abstract description 2
229940125723 sedative agent Drugs 0.000 abstract description 2
206010002383 Angina Pectoris Diseases 0.000 abstract 1
229940123907 Disease modifying antirheumatic drug Drugs 0.000 abstract 1
238000010586 diagram Methods 0.000 description 30
239000003814 drug Substances 0.000 description 13
238000002474 experimental method Methods 0.000 description 13
229940079593 drug Drugs 0.000 description 11
210000001061 forehead Anatomy 0.000 description 9
239000000725 suspension Substances 0.000 description 9
UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
239000004480 active ingredient Substances 0.000 description 6
230000000975 bioactive effect Effects 0.000 description 6
230000006378 damage Effects 0.000 description 6
229920002785 Croscarmellose sodium Polymers 0.000 description 5
229960004536 betahistine Drugs 0.000 description 5
230000008961 swelling Effects 0.000 description 5
VYVKHNNGDFVQGA-UHFFFAOYSA-N 3,4-dimethoxybenzoic acid 4-[ethyl-[1-(4-methoxyphenyl)propan-2-yl]amino]butyl ester Chemical compound C=1C=C(OC)C=CC=1CC(C)N(CC)CCCCOC(=O)C1=CC=C(OC)C(OC)=C1 VYVKHNNGDFVQGA-UHFFFAOYSA-N 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
235000010980 cellulose Nutrition 0.000 description 4
229960003529 diazepam Drugs 0.000 description 4
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 4
239000010410 layer Substances 0.000 description 4
230000014759 maintenance of location Effects 0.000 description 4
229960003577 mebeverine Drugs 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
230000000541 pulsatile effect Effects 0.000 description 4
239000000126 substance Substances 0.000 description 4
210000002700 urine Anatomy 0.000 description 4
238000002483 medication Methods 0.000 description 3
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 3
229960004618 prednisone Drugs 0.000 description 3
238000000926 separation method Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 2
238000005336 cracking Methods 0.000 description 2
230000003628 erosive effect Effects 0.000 description 2
230000029142 excretion Effects 0.000 description 2
238000004880 explosion Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000035699 permeability Effects 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
230000008569 process Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
239000002195 soluble material Substances 0.000 description 2
239000007916 tablet composition Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000167854 Bourreria succulenta Species 0.000 description 1
101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 description 1
241000282461 Canis lupus Species 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
241000283965 Ochotona princeps Species 0.000 description 1
108010019160 Pancreatin Proteins 0.000 description 1
240000000220 Panda oleosa Species 0.000 description 1
235000016496 Panda oleosa Nutrition 0.000 description 1
241001674048 Phthiraptera Species 0.000 description 1
235000016787 Piper methysticum Nutrition 0.000 description 1
240000005546 Piper methysticum Species 0.000 description 1
241000220317 Rosa Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000006732 Torreya nucifera Nutrition 0.000 description 1
244000111306 Torreya nucifera Species 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
229960004538 alprazolam Drugs 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
239000011247 coating layer Substances 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
230000035622 drinking Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
229960004038 fluvoxamine Drugs 0.000 description 1
CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
230000037406 food intake Effects 0.000 description 1
239000007789 gas Substances 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
208000002551 irritable bowel syndrome Diseases 0.000 description 1
OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical group OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
229940124641 pain reliever Drugs 0.000 description 1
229940055695 pancreatin Drugs 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000008028 pharmaceutical plasticizer Substances 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
230000010349 pulsation Effects 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000007958 sleep Effects 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000011179 visual inspection Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Virology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Psychiatry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Cosmetics (AREA)

UA99042314A 1996-09-23 1997-09-18 Oral delayed immediate release formulation and method for its manufacture UA72182C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP96202651		1996-09-23
PCT/EP1997/005234 WO1998013029A1 (en)	1996-09-23	1997-09-18	Oral delayed immediate release formulation and method of preparation therefor

Publications (1)

Publication Number	Publication Date
UA72182C2 true UA72182C2 (en)	2005-02-15

Family

ID=8224414

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA99042314A UA72182C2 (en)	1996-09-23	1997-09-18	Oral delayed immediate release formulation and method for its manufacture

Country Status (29)

Country	Link
US (1)	US6183780B1 (cs)
EP (1)	EP0939623B1 (cs)
JP (1)	JP4947824B2 (cs)
KR (1)	KR100501966B1 (cs)
CN (1)	CN1161110C (cs)
AT (1)	ATE213627T1 (cs)
AU (1)	AU717711B2 (cs)
BR (1)	BR9711303A (cs)
CA (1)	CA2263921C (cs)
CZ (1)	CZ294641B6 (cs)
DE (1)	DE69710756T2 (cs)
DK (1)	DK0939623T3 (cs)
DZ (1)	DZ2314A1 (cs)
ES (1)	ES2172003T3 (cs)
HR (1)	HRP970493A2 (cs)
HU (1)	HU226693B1 (cs)
ID (1)	ID22039A (cs)
IL (1)	IL128565A (cs)
JO (1)	JO2066B1 (cs)
NO (1)	NO325763B1 (cs)
NZ (1)	NZ334463A (cs)
PL (1)	PL189016B1 (cs)
PT (1)	PT939623E (cs)
RU (1)	RU2193395C2 (cs)
SK (1)	SK284263B6 (cs)
TR (1)	TR199900641T2 (cs)
UA (1)	UA72182C2 (cs)
WO (1)	WO1998013029A1 (cs)
ZA (1)	ZA978431B (cs)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030109503A1 (en) *	1995-06-06	2003-06-12	Smithkline Beecham P.L.C.	Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
EE200000693A (et)	1998-05-20	2002-04-15	The Liposome Company, Inc.	Uudsed makroosakeste formulatsioonid
SE9802973D0 (sv)	1998-09-03	1998-09-03	Astra Ab	Immediate release tablet
US6322819B1 (en) *	1998-10-21	2001-11-27	Shire Laboratories, Inc.	Oral pulsed dose drug delivery system
CA2348871C (en) *	1998-11-02	2009-04-14	John G. Devane	Multiparticulate modified release composition
US6294199B1 (en) *	1999-04-13	2001-09-25	Beecham Pharmaceuticals (Pte) Limited	Method of treating a bacterial infection comprising administering amoxycillin
US7250176B1 (en) *	1999-04-13	2007-07-31	Beecham Pharmaceuticals (Pte) Limited	Method of treating a bacterial infection
US6878386B1 (en)	1999-04-13	2005-04-12	Beecham Pharmaceuticals (Pte) Limited	Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
IE990406A1 (en) *	1999-05-20	2000-12-27	Elan Corp Plc	Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
EP1064937A1 (en) *	1999-06-28	2001-01-03	Sanofi-Synthelabo	Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
EP1074249A1 (en) *	1999-07-27	2001-02-07	Jagotec Ag	A pharmaceutical tablet system for releasing at least one active substance during a release period subsequent to a no-release period
HUP0202537A3 (en)	1999-08-24	2004-05-28	Teva Pharma	A vaccine composition and method of using the same
US6592869B2 (en)	1999-08-24	2003-07-15	Teva Pharmaceutical Industries, Ltd.	Vaccine composition and method of using the same
EP1206248B1 (en) *	1999-08-26	2003-06-04	Neurocrine Biosciences, Inc.	Controlled-release sedative-hypnotic compositions and methods related thereto
US6485746B1 (en)	2000-08-25	2002-11-26	Neurocrine Biosciences, Inc.	Controlled-release sedative-hypnotic compositions and methods related thereto
DE10012555A1 (de) *	2000-03-15	2001-09-20	Merck Patent Gmbh	Glucocorticoide in einer Modified Release-Formulierung
US6720005B1 (en) *	2000-07-07	2004-04-13	The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University	Coated, platform-generating tablet
US6756057B2 (en)	2000-10-12	2004-06-29	Beecham Pharmaceuticals (Pte) Limited	Amoxicillin and potassium clavulanate dosage form
WO2002030392A2 (en)	2000-10-12	2002-04-18	Beecham Pharmaceuticals (Pte) Limited	Formulation containing amoxicillin
US6913768B2 (en) *	2002-09-24	2005-07-05	Shire Laboratories, Inc.	Sustained release delivery of amphetamine salts
US20080220074A1 (en) *	2002-10-04	2008-09-11	Elan Corporation Plc	Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
ATE445393T1 (de) *	2003-04-24	2009-10-15	Jagotec Ag	Tablette mit gefärbtem kern
CN102525993B (zh)	2003-04-24	2017-04-12	佳高泰克有限公司	具有限定内核几何形状的缓释片剂
KR101087464B1 (ko) *	2003-08-08	2011-11-25	밸리언트 인터내셔널(바베이도스) 에스알엘	부프로피온 히드로클로라이드의 개질 방출형 정제
JP5105578B2 (ja)	2003-11-05	2012-12-26	サーコードバイオサイエンスインコーポレイテッド	細胞接着のモジュレーター
CA2568640C (en)	2004-06-04	2011-08-09	Teva Pharmaceutical Industries Ltd.	Pharmaceutical composition containing irbesartan
DE102004043863A1 (de)	2004-09-10	2006-03-16	Nitec Pharma Ag	Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum
GB0423964D0 (en) *	2004-10-28	2004-12-01	Jagotec Ag	Dosage form
US20060121112A1 (en) *	2004-12-08	2006-06-08	Elan Corporation, Plc	Topiramate pharmaceutical composition
JP2008535922A (ja) *	2005-04-12	2008-09-04	エラン・ファルマ・インターナショナル・リミテッド	細菌感染を治療するためのセファロスポリンを含む放出制御組成物
US8168655B2 (en)	2005-05-17	2012-05-01	Sarcode Bioscience Inc.	Compositions and methods for treatment of eye disorders
WO2007037790A2 (en) *	2005-06-08	2007-04-05	Elan Corporation, Plc	Modified release famciclovir compositions
DK1916995T4 (da)	2005-07-29	2022-10-03	Stichting Groningen Centre For Drug Res	Ph-styret, pulserende indgivelsessystem, fremgangsmåder til fremstilling og anvendelse deraf
US20070036859A1 (en) *	2005-08-11	2007-02-15	Perry Ronald L	Sustained release antihistamine and decongestant composition
TWI274889B (en) *	2005-10-06	2007-03-01	Elan Microelectronics Corp	Resistive touch screen measurement system
WO2007072495A2 (en) *	2005-11-03	2007-06-28	Sun Pharmaceutical Industries Limited	Coated tablets having prolonged gastric retention
RU2308941C1 (ru) *	2006-05-10	2007-10-27	Открытое акционерное общество "Московское производственное химико-фармацевтическое объединение им. Н.А. Семашко"	Твердая лекарственная форма, обладающая гистаминоподобным действием, и способ ее получения
SG174026A1 (en)	2006-08-03	2011-09-29	Nitec Pharma Ag	Delayed-release glucocorticoid treatment of rheumatoid disease
US20080081067A1 (en) *	2006-10-03	2008-04-03	Gupta Manishkumar	Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
RU2356539C2 (ru) *	2006-12-28	2009-05-27	Закрытое Акционерное Общество "Канонфарма Продакшн"	Твердая лекарственная форма бетагистина дигидрохлорида и способ ее получения
MX2009013293A (es)	2007-06-04	2010-02-15	Synergy Pharmaceuticals Inc	Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009021127A2 (en) *	2007-08-07	2009-02-12	Neurogen Corporation	Controlled released compositions
MX2010004281A (es)	2007-10-19	2010-09-10	Sarcode Corp	Composiciones y metodos para el tratamiento de la retinopatia diabetica.
WO2009139817A2 (en)	2008-04-15	2009-11-19	Sarcode Corporation	Crystalline pharmaceutical and methods of preparation and use thereof
EP2810951B1 (en)	2008-06-04	2017-03-15	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en)	2008-07-16	2019-09-24	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2010207740B2 (en) *	2009-01-26	2016-06-16	Nitec Pharma Ag	Delayed-release glucocorticoid treatment of asthma
NZ582836A (en) *	2009-01-30	2011-06-30	Nitec Pharma Ag	Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
US8378105B2 (en)	2009-10-21	2013-02-19	Sarcode Bioscience Inc.	Crystalline pharmaceutical and methods of preparation and use thereof
EP2314296A1 (en) *	2009-10-22	2011-04-27	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Orally Disintegrating Tablets of Betahistine
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
WO2012071220A1 (en) *	2010-11-23	2012-05-31	Transcept Pharmaceuticals, Inc.	Compositions and methods for once-daily administration of a trilayer osmotic tablet
RU2453308C1 (ru) *	2010-12-20	2012-06-20	Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ"	Драже с оксиметилурацилом и мебеверина гидрохлоридом для лечения функциональных заболеваний желудочно-кишечного тракта
KR102258769B1 (ko) *	2011-10-14	2021-06-01	지엘팜텍주식회사	장용소화효소제 및 그 제조방법
DE102012105528A1 (de)	2012-06-25	2014-01-02	Hennig Arzneimittel Gmbh & Co. Kg	Arzneiform zur Freisetzung von Wirkstoffen
SI3715345T1 (sl)	2012-07-25	2024-07-31	Bausch + Lomb Ireland Limited	Priprava zaviralca lfa-1
EP3718557A3 (en)	2013-02-25	2020-10-21	Bausch Health Ireland Limited	Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing
JP2016514670A (ja)	2013-03-15	2016-05-23	シナジーファーマシューティカルズインコーポレイテッド	他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
JP2016514671A (ja)	2013-03-15	2016-05-23	シナジーファーマシューティカルズインコーポレイテッド	グアニル酸シクラーゼのアゴニストおよびその使用
WO2015054649A2 (en)	2013-10-10	2015-04-16	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
NO346258B1 (en) *	2015-06-30	2022-05-16	Neurad Ltd	Novel breathing control modulating compounds, and methods of making and using same
JP2019506383A (ja)	2016-01-11	2019-03-07	シナジーファーマシューティカルズインコーポレイテッド	潰瘍性大腸炎を治療するための製剤および方法
CN108836948B (zh) *	2018-06-11	2024-04-12	宁波西敦医药包衣科技有限公司	一种利用包衣技术实现营养素可控制释放的产品
RU2695135C1 (ru) *	2018-07-11	2019-07-22	Федеральное государственное унитарное предприятие "Научно-исследовательский институт гигиены, профпатологии и экологии человека" Федерального медико-биологического агентства	Двухуровневая микрогранулированная форма терапевтического пептида для перорального применения и способ ее получения
CN110403912A (zh) *	2019-09-04	2019-11-05	西安科力康医药科技有限公司	缓控释包衣粉

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH666405A5 (de) *	1985-06-24	1988-07-29	Ciba Geigy Ag	Feste, haltbare darreichungsformen mit elastischem filmueberzug.
GB8524001D0 (en) *	1985-09-30	1985-11-06	Glaxo Group Ltd	Pharmaceutical composition
US5122384A (en) *	1989-05-05	1992-06-16	Kv Pharmaceutical Company	Oral once-per-day organic nitrate formulation which does not induce tolerance
US5133974A (en) *	1989-05-05	1992-07-28	Kv Pharmaceutical Company	Extended release pharmaceutical formulations
US5032405A (en) *	1989-09-27	1991-07-16	Warner-Lambert Company	Oral pharmaceutical composition for acid sensitive proteinaceous agents
FR2655266B1 (fr) *	1989-12-05	1992-04-03	Smith Kline French Lab	Compositions pharmaceutiques a base de cimetidine.
US5229131A (en) *	1990-02-05	1993-07-20	University Of Michigan	Pulsatile drug delivery system
US5158777A (en) *	1990-02-16	1992-10-27	E. R. Squibb & Sons, Inc.	Captopril formulation providing increased duration of activity
GB9104854D0 (en) *	1991-03-07	1991-04-17	Reckitt & Colmann Prod Ltd	Sustained release compositions
US5286497A (en)	1991-05-20	1994-02-15	Carderm Capital L.P.	Diltiazem formulation
AU661080B2 (en) *	1991-11-22	1995-07-13	Warner Chilcott Company, Llc	Risedronate delayed-release compositions
WO1993019741A1 (en) *	1992-03-31	1993-10-14	Benzon Pharma A/S	A pharmaceutical formulation
US5500227A (en) *	1993-11-23	1996-03-19	Euro-Celtique, S.A.	Immediate release tablet cores of insoluble drugs having sustained-release coating
EP0758244B2 (en) *	1994-05-06	2008-02-13	Pfizer Inc.	Controlled-release dosage forms of azithromycin

1997
- 1997-09-16 HR HR96202651,4A patent/HRP970493A2/hr not_active Application Discontinuation
- 1997-09-18 EP EP97943895A patent/EP0939623B1/en not_active Expired - Lifetime
- 1997-09-18 AU AU45570/97A patent/AU717711B2/en not_active Ceased
- 1997-09-18 PT PT97943895T patent/PT939623E/pt unknown
- 1997-09-18 IL IL12856597A patent/IL128565A/xx not_active IP Right Cessation
- 1997-09-18 JP JP51526398A patent/JP4947824B2/ja not_active Expired - Fee Related
- 1997-09-18 DE DE69710756T patent/DE69710756T2/de not_active Expired - Lifetime
- 1997-09-18 NZ NZ334463A patent/NZ334463A/xx not_active IP Right Cessation
- 1997-09-18 TR TR1999/00641T patent/TR199900641T2/xx unknown
- 1997-09-18 UA UA99042314A patent/UA72182C2/uk unknown
- 1997-09-18 RU RU99108461/14A patent/RU2193395C2/ru not_active IP Right Cessation
- 1997-09-18 BR BR9711303A patent/BR9711303A/pt not_active Application Discontinuation
- 1997-09-18 AT AT97943895T patent/ATE213627T1/de active
- 1997-09-18 SK SK376-99A patent/SK284263B6/sk not_active IP Right Cessation
- 1997-09-18 CZ CZ1999995A patent/CZ294641B6/cs not_active IP Right Cessation
- 1997-09-18 PL PL97332245A patent/PL189016B1/pl not_active IP Right Cessation
- 1997-09-18 DK DK97943895T patent/DK0939623T3/da active
- 1997-09-18 ES ES97943895T patent/ES2172003T3/es not_active Expired - Lifetime
- 1997-09-18 ZA ZA9708431A patent/ZA978431B/xx unknown
- 1997-09-18 CA CA002263921A patent/CA2263921C/en not_active Expired - Fee Related
- 1997-09-18 CN CNB971981671A patent/CN1161110C/zh not_active Expired - Fee Related
- 1997-09-18 WO PCT/EP1997/005234 patent/WO1998013029A1/en not_active Ceased
- 1997-09-18 ID IDW990114A patent/ID22039A/id unknown
- 1997-09-18 KR KR10-1999-7002380A patent/KR100501966B1/ko not_active Expired - Fee Related
- 1997-09-18 HU HU9904121A patent/HU226693B1/hu not_active IP Right Cessation
- 1997-09-19 US US08/934,196 patent/US6183780B1/en not_active Expired - Lifetime
- 1997-09-21 JO JO19972066A patent/JO2066B1/en active
- 1997-09-22 DZ DZ970164A patent/DZ2314A1/xx active
1999
- 1999-03-22 NO NO19991385A patent/NO325763B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
JP4947824B2 (ja)	2012-06-06
CZ99599A3 (cs)	1999-06-16
BR9711303A (pt)	1999-08-17
HK1019852A1 (en)	2000-03-03
US6183780B1 (en)	2001-02-06
WO1998013029A1 (en)	1998-04-02
IL128565A0 (en)	2000-01-31
EP0939623B1 (en)	2002-02-27
DE69710756T2 (de)	2002-10-24
PT939623E (pt)	2002-08-30
HUP9904121A3 (en)	2004-10-28
DE69710756D1 (de)	2002-04-04
AU717711B2 (en)	2000-03-30
DK0939623T3 (da)	2002-06-10
NO991385D0 (no)	1999-03-22
CA2263921A1 (en)	1998-04-02
CN1161110C (zh)	2004-08-11
CA2263921C (en)	2006-05-23
KR100501966B1 (ko)	2005-07-20
JO2066B1 (en)	2000-05-21
KR20010029536A (ko)	2001-04-06
NO991385L (no)	1999-05-25
CZ294641B6 (cs)	2005-02-16
PL189016B1 (pl)	2005-06-30
AU4557097A (en)	1998-04-17
ES2172003T3 (es)	2002-09-16
SK37699A3 (en)	1999-08-06
PL332245A1 (en)	1999-08-30
SK284263B6 (sk)	2004-12-01
IL128565A (en)	2003-02-12
HU226693B1 (en)	2009-06-29
ATE213627T1 (de)	2002-03-15
ZA978431B (en)	1998-03-26
DZ2314A1 (fr)	2002-12-28
ID22039A (id)	1999-08-26
NZ334463A (en)	2000-12-22
JP2001500885A (ja)	2001-01-23
TR199900641T2 (xx)	1999-07-21
CN1231601A (zh)	1999-10-13
HUP9904121A2 (hu)	2000-04-28
HRP970493A2 (en)	1998-08-31
EP0939623A1 (en)	1999-09-08
NO325763B1 (no)	2008-07-14
RU2193395C2 (ru)	2002-11-27

Publication	Publication Date	Title
AU717711B2 (en)	2000-03-30	Oral delayed immediate release formulation and method of preparation therefor
US20230086496A1 (en)	2023-03-23	Fast Dissolving Solid Dosage Form
EP1753407B1 (en)	2017-03-08	Sugar coatings and methods therefor
JP2000515871A (ja)	2000-11-28	トラマドール複式ユニット製剤
JP5907945B2 (ja)	2016-04-26	速溶解性医薬組成物
JP2006521301A (ja)	2006-09-21	薬剤物質の送達制御用マトリックス組成物
CN101394840A (zh)	2009-03-25	旨在避免非主观误服和非法滥服的抗张性羟考酮片剂
MX2015006399A (es)	2015-07-21	Composicion para la liberacion inmediata y prolongada.
CN102198140A (zh)	2011-09-28	具有改进的药物代谢动力学特性的药物
Mehta et al.	2010	An emerging trend in oral drug delivery technology: rapid disintegrating tablets
Roshan et al.	2021	Orodispersible tablets: A compendious review
Sah et al.	2016	Sublingual tablets: an overview
RS58543B2 (sr)	2023-02-28	Optimizovana farmaceutska formulacija za lečenje zapaljenskih promena ezofagusa
WO2006111085A1 (en)	2006-10-26	A method, formulation and use thereor with improved oral absorption of drugs or nutrients
EP2939661B1 (en)	2022-11-23	Novel microgranular formulation
Kumar et al.	2019	Fast dissolving tablets: better option for pediatrics and geriatrics
HK1019852B (en)	2002-06-07	Oral delayed immediate release formulation and method of preparation therefor
ES2430333T3 (es)	2013-11-20	Composiciones de matriz para liberación controlada de principios activos
Alanezi	2014	Development of an orally disintegrating mini-tablet (ODMTs) containing metoclopramide HCl to enhance patient compliance
Kaur et al.	2014	preparation and characterization of fast disintegrating tablets of hydralazine hydrochloride using design of experiment technique
NZ730379B2 (en)	2024-01-30	Eutectic formulations of cyclobenzaprine hydrochloride